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In this issue of the Journal, Mehta et al. (1) address the
question as to whether patients suffering an acute myocar-
dial infarction (MI) would be better served presenting to a
hospital with coronary revascularization capabilities. To
answer this question adequately in the year 2002, two
separate issues need be addressed. The first relates to
whether patients with an acute ST-segment elevation MI
are better served by primary angioplasty (percutaneous
coronary intervention [PCI]) rather than thrombolysis, and
if primary PCI is superior, whether this needs to be done at
the hospital of presentation or can patients be transferred to
regional centers where large volumes assure good results (2).
The second question, addressed by the investigators, is
whether patients receiving thrombolysis are better served by
presenting to a hospital with coronary revascularization
capabilities.
See page 1034
PRIMARY PCI VERSUS THROMBOLYSIS: NEED
FOR PRESENTATION TO A HOSPITAL WITH
CORONARY REVASCULARIZATION CAPABILITIES
The Primary Angioplasty in Myocardial Infarction (PAMI)
study in 1993 (3) suggested that, in experienced hands,
primary PCI was superior to thrombolysis in patients
presenting with an acute ST-segment elevation MI. A
meta-analysis by Yusuf and Pogue (4) re-enforced this
concept, and the SHould we emergently revascularize Oc-
cluded Coronaries in cardiogenic shocK (SHOCK) trial (5)
clearly established the benefits of early mechanical reperfu-
sion with PCI or coronary artery bypass grafting (CABG) in
patients with acute MI complicated by cardiogenic shock.
Whether patients suffering an acute ST-segment elevation
MI need to have primary PCI in their hospital of presen-
tation or whether they can safely be transferred to a regional
center to have PCI has recently been studied. The most
comprehensive of these is the Danish Multicenter Random-
ized Study on Thrombolytic Therapy versus Acute Coro-
nary Angioplasty in Acute Myocardial Infarction
(DANAMI-2) that was reported at the American College
of Cardiology Scientific Sessions in March 2002. In that
study, 1,572 patients suffering from an acute ST-segment
elevation MI were randomized to front-loaded tissue-type
plasminogen activator (t-PA) or PCI if they presented
within 12 h of onset of their MI. A significant proportion of
patients (n  1,129) presented to a center without revascu-
larization capabilities and required being transferred. All
patients assigned to primary PCI received treatment within
3 h of randomization. The study was discontinued prema-
turely owing to clear benefit in the combined end point of
death, reinfarction, and disabling stroke (40% reduction in
the combined end point at 30 days, p  0.003). Interest-
ingly, there was little difference in delay for PCI whether a
patient presented to an interventional facility or required
transfer from a noninterventional hospital, and no deaths
occurred during transfer. Importantly, no difference in
benefit with the PCI strategy was noted between patients
presenting to a hospital with or without coronary revascu-
larization capabilities.
Two other studies support the results of the DANAMI-2
trial. The first is the PRimary Angioplasty in patients
transferred from General community hospitals to special-
ized PTCA Units with or without Emergency thrombolysis
(PRAGUE) study (6), in which transfer for primary PCI,
thrombolysis, and immediate transfer for PCI and throm-
bolysis with ischemia-driven transfer were compared in 300
patients with ST-segment elevation MI. A significant
reduction in 30-day death, MI, and stroke was reported for
primary PCI compared to the other two strategies (8% vs.
15% vs. 23%, respectively, p  0.02). Admittedly, strep-
tokinase was the thrombolytic agent utilized in this trial.
Finally, the Air Primary Angioplasty in Myocardial
Infarction (AIR PAMI) trial, cited by the investigators
attempted to deal directly with the issue of routine transfer
of acute MI patients to an interventional facility in the U.S.
in a randomized trial of transfer for primary PCI versus
thrombolysis. As Mehta et al. (1) point out, the trial was
terminated early because of poor patient enrollment, and no
difference in outcome was noted at that time. However, a
38% reduction in major adverse cardiac events was observed
in the 138 patients randomized to PCI, despite a delay in
treatment of 155 min. Taken together, these studies are
highly suggestive that, if appropriate facilities for rapid
patient transfer are available, the benefits of primary PCI
over thrombolysis are maintained and equivalent regardless
of whether a patient presents to a hospital with coronary
revascularization capabilities or a center without such facil-
ities.
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PATIENTS RECEIVING THROMBOLYSIS:
NEED TO PRESENT TO A HOSPITAL WITH
CORONARY REVASCULARIZATION CAPABILITIES
Mehta et al. (1) conclude that patients receiving thrombol-
ysis for a ST-segment elevation MI obtain no benefit from
presenting to a hospital with coronary revascularization
capabilities. They correctly cite data from registries per-
formed in the U.S. between 1988 to 1996, all supporting
their conclusions (7–10). Data from comparisons between
the U.S. and Canada performed during that period yielded
more complex results (11–13). Although still somewhat
controversial, these studies suggest that there may be a
short-term benefit associated with greater use of invasive
revascularization procedures in the U.S., but that this
benefit, at least as it relates to survival, disappears by one
year.
How then do we reconcile the differences in outcome
related to the greater use of invasive diagnostic and thera-
peutic procedures in Canada and the U.S. with the lack of
difference reported by Mehta et al. (1) and various other
studies done within the U.S.? The answer is certainly
complex, possibly being related in part to differences in the
use of medications. However, it may also be the result of a
threshold below which there is a clear benefit from the use
of invasive diagnostic and therapeutic interventions. In favor
of this possibility is the very low use of coronary angiogra-
phy in Canada versus the U.S. (6.7% vs. 34.9%, respectively)
and the very low use of revascularization procedures (2.9%
vs. 22.3%, respectively) in the only study that demonstrated
a survival benefit post-MI in the U.S. (11). In the two other
studies (12,13), the use of invasive diagnostic (25% and
35%) and revascularization procedures (13% and 14%) in
Canada was greater than the one study showing a short-
term difference in survival (a study done exclusively in
patients over 65 years of age) (11). It should be noted,
however, that even in the one study that demonstrated a
difference in survival at 30 days (77.7% in Canada vs. 78.6%
in the U.S., p  0.03) this difference disappeared by one
year (65.6% in Canada vs. 65.7% in the U.S.).
Previous reports evaluating the effect of on-site availabil-
ity or use of coronary revascularization have all been
registries and thus better reflect effects in the entire popu-
lation. However, data from randomized trials add comple-
mentary information that, although less generalizable, con-
trols for more variables and provides more precise
information in the population studied. In this way, this
analysis of the Global Utilization of Streptokinase and
Tissue Plasminogen Activator for Occluded Coronary
Arteries-1 (GUSTO-1) study is important. The investiga-
tors found a borderline improvement of 30-day survival in
patients admitted to centers with coronary revascularization
capabilities. When adjusted for the baseline risk factors
found to be the most predictive of survival in the overall
GUSTO-1 study—that is, age, systolic blood pressure,
heart rate, Killip class, and MI location—this improvement
became insignificant. The MITI (Myocardial Infarction
Triage and Intervention) registry (9) also demonstrated a
tendency for improved in-hospital survival in centers with
coronary revascularization capabilities (relative risk [RR]
0.88, [95% confidence interval (CI) 0.71 to 1.09]), as did a
large registry reported by Rogers et al. (7) at six months’
post-MI (RR 0.92, [CI 0.83 to 1.01]). This raises the
question as to whether a real difference exists and whether
their adjustments for severity of disease included all poten-
tially important variables.
Mehta et al. (1) justify their model by telling us that these
five variables make up approximately 90% of the total
chi-square of their model. It is, however, very difficult to
adjust for all differences between groups. In a previous study
of consecutive patients admitted with an acute MI in
Canada (14), despite adjusting for important variables,
which included left ventricular ejection fraction, we were
unable to eliminate an inverse relationship between patient
acuity and survival. In the study by Mehta et al. (1), several
potentially important differences in patient acuity were
noted, most of which were not included in their adjustment
model and would favor a widening of the RR reduction in
centers with revascularization capabilities. These include
more prior MI, hypertension, prior revascularization, and
greater use of ventilators and pacemakers in patients from
the centers with revascularization capabilities.
These concerns notwithstanding, the results of survival at
one year in the present study clearly indicate no difference
between groups such that if borderline differences existed in
survival at 30 days, they do not persist. A loss of potential
early differences in survival by one year was also found in the
MITI registry (hazard ratio of 1.0 [95% CI 0.93 to 1.1]),
and in the one Canada–U.S. comparison that demonstrated
an association between greater use of invasive diagnostic and
therapeutic interventions and survival. Thus, as outlined by
the researchers (1), whether an early benefit in centers with
coronary revascularization capabilities exists or not, the
differences do not persist.
It bears mentioning that the GUSTO-1 study was
performed a decade ago and that medical as well as PCI
techniques have evolved. Mehta et al. (1) point out that few
new interventions that would modify their results have
appeared since then. This may be true for individual
developments (except angiotensin-converting enzyme
[ACE] inhibitors), but it is possible that, when combined,
these could influence the results of such an analysis if it were
done in 2002. These include ACE inhibitors, clopidogrel,
the use of coronary stents, platelet glycoprotein IIb/IIIa
receptor inhibitors, lipid-modifying agents, and low molec-
ular weight heparin.
One final cautionary note with respect to the interpreta-
tion of the study by Mehta et al. (1). In the GUSTO-1
study, the number of patients transferred for invasive diag-
nostic and revascularization procedures was reasonably high
in the centers without revascularization capabilities, 59.2%.
Thus, the threshold for invasive diagnostic and therapeutic
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interventions was low, such that the conclusions of the
investigators can only be said to hold true if there is liberal
use of regional coronary diagnostic and revascularization
facilities. Their results cannot be extrapolated to situations
where there is less use of diagnostic and therapeutic proce-
dures. Also, while the reported rates of cardiac catheteriza-
tion were quite high in centers with and without revascu-
larization capabilities (78.1% and 59.2%, respectively), the
rates of revascularization were considerably lower in both
types of institutions. It is unclear as to whether this
represents rates based on knowledge of anatomy and isch-
emia or a less interventional bias of treating physicians in
the early 1990s. It is unlikely that a similar pattern would be
observed in contemporary practice.
Conclusions. At this time, the weight of the evidence
supports the conclusions of Mehta et al. (1), namely that
when suffering from an acute MI, when receiving throm-
bolysis, there is no survival benefit in presenting to a
hospital with coronary revascularization capabilities. Recent
studies documenting the benefits of primary PCI in patients
presenting with an MI to a hospital without coronary
revascularization capabilities would suggest that their con-
clusions may hold true for primary PCI as well, if proper
emergent patient transfer is available. The study (1) in this
issue of the Journal, however, does not address the possibil-
ity that there could be differences in the outcome of patients
presenting to centers without revascularization facilities
where timely (2 to 3 h) access to primary PCI is not
possible. Nonetheless, because of resource allocation issues,
in the majority of healthcare settings in the world today,
thrombolysis will continue to be the only feasible primary
reperfusion modality rendering the results of the Mehta et
al. (1) study important.
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